New biologic outperforms omalizumab in urticaria

A novel anti-IgE antibody drug ligelizumab allows more than half of patients with  chronic spontaneous urticaria to clear symptoms, a phase 2 trial has shown. Published in the NEJM, the 12-week results for the biologic showed that 51% of the patients treated with ligelizumab had complete control of urticaria, as compared with 26% of the ...

Already a member?

Login to keep reading.

© 2021 the limbic